This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

milvexian
Medical Information

Milvexian -  The Effect of Moderate or Severe Renal Impairment on the Pharmacokinetic Properties of Milvexian

Last Updated: 11/20/2026

SUMMARY

  • This document outlines the pharmacokinetics (PK) of milvexian (BMS-986177/JNJ-70033093) in participants with normal renal function and participants with moderate or severe renal impairment.1
  • Milvexian is an orally active, small molecule that inhibits the active form of factor XI (FXIa) with high affinity and selectivity.1
  • Milvexian has demonstrated antithrombotic activity in preclinical models of arterial and venous thrombosis while preserving hemostasis and was generally well tolerated in phase 1 studies in healthy participants and in individuals with hepatic impairment.2-5
  • Safety: A single dose of milvexian 60 mg was well tolerated in participants with normal renal function and participants with moderate or severe renal impairment.1
  • Outcomes: A regression analysis indicated that maximum observed plasma concentration (Cmax) was similar for all renal function groups, while area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-T]) and AUC from time zero extrapolated to infinite time (AUC[INF]) increased with decreasing estimated glomerular filtration rate (eGFR) and creatinine clearance (CrCl).1

BRISTOL MYERS SQUIBB AND JOHNSON & JOHNSON COLLABORATION

Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.

To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.

To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.

CLINICAL DATA

Effect of Renal Impairment on PK Properties of Milvexian

Perera et al (2022)1 conducted an open-label, parallel-group study to assess the PK, safety, and tolerability of a single oral 60 mg dose of milvexian in participants with normal renal function and moderate or severe renal impairment.

Study Design/Methods1-3

OBJECTIVE: To assess the effect of moderate and severe renal impairment on the PK properties of milvexian.

STUDY DESIGN: Open-label, nonrandomized, parallel group study of 3 renal function groups.

  • PARTICIPANTS AND COHORTS:
    • Key inclusion criteria: Participants aged 18 to 70 years with a body mass index (BMI) of 18.0 to 32.0 kg/m2 for participants with normal renal function or 18.0 to 38.0 kg/m2 for participants with moderate or severe renal impairment.
    • Key exclusion criteria: Participants on dialysis or with an indwelling catheter in preparation for hemodialysis, history of coagulopathy, gastrointestinal disease, or any major surgery within 4 weeks of study treatment administration (or planned within 2 weeks of study completion).
    • Participants were enrolled in a renal function group based on eGFR, which was determined by the Modification of Diet in Renal Disease formula (MDRD). See Table: Baseline Characteristics for additional information.
      • Normal renal function: eGFR ≥ 90 mL/min/1.73 m2 (n = 8).
      • Moderate renal impairment: eGFR ≥ 30 to ≤ 59 mL/min/1.73 m2 (n = 8).
      • Severe renal impairment: eGFR < 30 mL/min/1.73 m2 (n = 8).
    • Study treatments:
      • On Day 1, all participants received a single oral dose of milvexian 60 mg after consumption of a standard meal.
      • Blood and urine samples were collected at screening and on Days −1, (2 in moderate and severe renal impairment groups only) and 4 for PK analysis.
    • ENDPOINTS:
      • Safety and tolerability were assessed based on medical review of adverse event (AE) reports, vital sign measurements, electrocardiogram (ECG) measurements, physical examinations, and clinical laboratory tests.
      • PK parameters derived from the respective plasma concentration versus time and urinary excretion data using noncompartmental methods included: Cmax, time to Cmax (Tmax); AUC(0-T), AUC(INF), terminal plasma half-life (T1/2), apparent total body clearance (CLT/F), fraction of unbound drug (fu), Cmax of free drug (Cmax fu), AUC(0-T) of free drug (AUC[0-T] fu), AUC(INF) of free drug (AUC[INF] fu), apparent total body clearance of free drug (CLT/F fu), renal clearance (CLR), total amount recovered in the urine (Urt), percent dose of milvexian total amount recovered in urine (%Urt), and protein binding.
      • Activated partial thromboplastin time (aPTT) and FXI clotting activity were assessed as exploratory pharmacodynamic biomarkers.

Baseline Characteristics1
Characteristica
Normal renal function
(n = 8)
Moderate renal impairment
(n = 8)
Severe renal impairment
(n = 8)
Total
(n = 24)
Male gender, n (%)
7 (87.5)
6 (75.0)
5 (62.5)
18 (75.0)
Age, y
Median (range)
53.5 (30 to 67)
63.0 (46 to 70)
61.5 (27 to 70)
60.0 (27 to 70)
Race, n (%)
White
Black or African American
Asian
Biracial
6 (75.0)
1 (12.5)
0
1 (12.5)
7 (87.5)
0
1 (12.5)
0
5 (62.5)
3 (37.5)
0
0
18 (75.0)
4 (16.7)
1 (4.2)
1 (4.2)
BMI, kg/m2
Median (range)
30.90 (19.6 to 31.5)
34.60 (24.3 to 37.5)
32.75 (20.4 to 37.9)
31.45 (19.6 to 37.9)
eGFR, mL/min/1.73 m2
Median (range)
104.5 (91 to 157)
49.0 (36 to 59)
20.5 (9 to 26)
-
CrCl, mL/min
Median (range)
125.0 (104 to 174)
67.0 (44 to 83)
32.0 (11 to 37)
-
aAll values presented as median (minimum-maximum) unless otherwise stated.
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; CrCl, creatinine clearance.
Table from Perera V et al. Clinical Pharmacokinetics. 2022;61:1405–1416.

Key Results

Pharmacokinetics

Mean concentrations of milvexian were higher in participants with moderate or severe renal impairment compared with participants with normal renal function following a single dose of milvexian.1

Mean (±SD) milvexian plasma concentration versus time profile1

Abbreviations: SD, standard deviation.

Figure from Perera V et al. Clinical Pharmacokinetics. 2022;61:1405–1416.

PK parameters are summarized in the table below.1


Summary Statistics of Milvexian Plasma and Urine Pharmacokinetic Parameters by Renal Function Group1
Parametera
Normal renal function
(n = 8)
Moderate renal impairment
(n = 8)
Severe renal impairment
(n = 8)
Cmax, ng/mL
462 (30)
406 (46)
462 (42)
%fu
8.85 (8)
8.81 (11)
8.40 (15)
Cmax fu, ng/mL
40.9 (29)
35.8 (44)
38.8 (44)
AUC(0-t), ng·h/mL
3860 (36)
5004 (34)
7094 (33)
AUC(0-t) fu, ng·h/mL
341 (33)
441 (32)
596 (41)
AUC(INF), ng·h/mL
3916 (36)
5154 (32)
7411 (37)
AUC(INF) fu, ng·h/mL
347 (34)
454 (30)
623 (44)
AUC(0-96), ng·h/mL
3883 (36)
5015 (34)
7167 (35)
Tmax, h
4.50 (4.00–5.00)
4.75 (4.00–7.00)
5.00 (4.50–8.00)
T½, h
13.8 (3.45)
18.0 (5.37)
17.7 (4.75)
CLT/F, L/h
15.3 (36)
11.6 (32)
8.10 (37)
CLT/F fu, L/h
173 (33)
132 (30)
96.4 (44)
CLR, mL/h
1617 (52)
914 (40)
263 (65)
%Urt
10.5 (45)
7.64 (33)
3.14 (75)
%Protein binding
91.1 (1)
91.1 (1)
91.5 (1)
aCmax, %fu, Cmax fu, AUC(0-t), AUC(0-t) fu, AUC(INF), AUC(INF) fu, AUC(0-96), CLT/F, CLT/F fu, CLR, %Urt, and %protein binding are presented as adjusted geometric mean (%CV); Tmax is presented as median (minimum–maximum); and T½ is presented as mean (SD).
Abbreviations: Cmax, maximum observed plasma concentration; fu, fraction of unbound drug; Cmax fu, maximum observed plasma concentration of free drug; AUC(0-t), area under the plasma concentration time curve from time zero to time of the last quantifiable concentration; AUC(0-t) fu, AUC from time zero to time of the last quantifiable concentration of free drug; AUC(INF), AUC from time zero extrapolated to infinite time; AUC(INF) fu, AUC from time zero extrapolated to infinite time of free drug; AUC(0-96), AUC from time zero to 96 h; Tmax, time of maximum observed plasma concentration; T½, terminal plasma half-life; CLT/F, apparent total body clearance; CLT/F fu, apparent total body clearance of free drug; CLR, renal clearance; %Urt, percentage dose of milvexian total amount recovered in urine; %CV, percentage coefficient of variation; SD, standard deviation.
Table from Perera V et al. Clinical Pharmacokinetics. 2022;61:1405–1416.

A regression analysis indicated that Cmax was similar for all renal functional groups.1

The AUC(0-T) increased by 39% and 50% in participants with eGFR 30 and 15 mL/min/1.73 m2, respectively, compared to those with normal renal function (eGFR 90 mL/min/1.73 m2). The AUC(0-T) increased by 38% and 49% in participants with CrCl 30 and 15 mL/min, respectively, compared to those with normal renal function (CrCl 90 mL/min).1

The AUC(INF) increased by 41% and 54% in participants with eGFR 30 and 15 mL/min/1.73 m2, respectively, compared to those with normal renal function (eGFR 90 mL/min/1.73 m2). The AUC(INF) increased by 40% and 52% in participants with CrCl 30 and 15 mL/min, respectively, compared to those with normal renal function (CrCl 90 mL/min).1

Predicted Values of Milvexian PK Parameters Based on Renal Impairment From the Regression Analysis of eGFR and CrCl in a) Moderate and b) Severe Renal Impairment1

Abbreviations: PK, pharmacokinetic; eGFR, estimated glomerular filtration rate; CrCl, creatinine clearance; GMR, geometric

mean ratio; CI, confidence interval; Cmax, maximum observed concentration; AUC(0-t), area under the plasma concentration-time curve from

time zero to time of the last quantifiable concentration; AUC(INF), area under the plasma concentration-time curve from time zero extrapolated to infinite time.

Figure from Perera V et al. Clinical Pharmacokinetics. 2022;61:1405–1416.

Pharmacodynamics

Mean baseline (predose Day 1) aPTT values were similar across renal function groups and ranged from 23.9 to 25.3 seconds.1

Administration of a single oral dose of milvexian resulted in a concentration-dependent prolongation of aPTT that was similar across all renal function groups.1

Mean (± SD) aPTT Versus Time Profile1

Abbreviations: aPTT, activated partial thromboplastin time; h, hours; SD, standard deviation, sec, seconds.

Figure from Perera V et al. Clinical Pharmacokinetics. 2022;61:1405–1416.

Safety and Tolerability

There were no deaths or serious AEs leading to discontinuation during the study and no bleeding events were reported.1

  • Overall, 3 participants reported 1 AE following administration of milvexian.1
    • Two participants reported headache and one reported somnolence.
    • All AEs were mild in intensity and considered by the investigator to be related to study treatment.
  • There were no clinically relevant findings or trends in clinical laboratory test, ECG, vital sign, or physical examination results.1

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 10 February 2026.

References

1 Perera V, Abelian G, Li D, et al. Single-dose pharmacokinetics of milvexian in participants with normal renal function and participants with moderate or severe renal impairment. Clin Pharmacokinet. 2022;61(10):1405-1416.  
2 Wong P, Crain E, Bozarth J, et al. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits. J Thromb Haemost. 2022;20(2):399-408.  
3 Wang X, Qiu L, Du F, et al. Antithrombotic effects of a novel small molecule FXIa inhibitor BMS-986177/JNJ-70033093 in a rabbit AV-shunt model of thrombosis. Poster presented at: 28th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH); July 12-14, 2020 (Virtual); PB0179.  
4 Perera V, Wang Z, Luettgen J, et al. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci. 2022;15(2):330-342.  
5 Perera V, Abelian G, Li D, et al. Single-dose pharmacokinetics of milvexian in participants with mild or moderate hepatic impairment compared with healthy participants. Clin Pharmacokinet. 2022;61(6):857-867.  

Would you like to clear and leave your conversation? Message history will be lost.